EuroAPI benefits from EU project

The European Commission has approved the first Important Project of Common European Interest (IPCEI). Under IPCEI Med4Cure, member states will provide up to €1 billion in public funding, which is expected to unlock €5.9 billion more in private funding.

IPCEI Med4Cure aims at foster the resilience of the EU health industry by enhancing drug discovery, in particular for unmet medical needs, and developing new, more sustainable production processes for pharmaceuticals. As well as improving the quality of healthcare contributing to the green transition, it will seek to boost the EU's preparedness for emerging health.

In all, 13 EU companies, including nine SMEs, will undertake 14 projects. Among these is French-based CDMO EuroAPI, which will use the funding to:

* Reshore production of macrolide antibiotics for the treatment of infectious diseases to its Saint-Aubin-lès-Elbeuf site

* Develop new processes and technologies for corticosteroids at its Vertolaye suite

* Increase the bioavailability of finding new therapeutic applications for the APIs using nanoparticles, also at Vertolaye

The French government and EuroAPI will now be able to begin discussions to prepare the contractual agreement for the granting of public aid within the framework of the France 2030 programme. Sanofi, from which EuroAPI was originally spun out, is another of the companies participating.